c-Cbl protein functions as an E3 ligase and scaffolding protein, where three residues, Y700, Y731, and Y774, upon phosphorylation, have been shown to initiate several signaling cascades. In this study, we investigated the role of these phospho-tyrosine residues in the platelet functional responses upon integrin engagement. We observed that c-Cbl Y700, Y731 and Y774 undergo phosphorylation upon platelet adhesion to immobilized fibrinogen, which was inhibited in the presence of PP2, a pan-src family kinase (SFK) inhibitor, suggesting that c-Cbl is phosphorylated downstream of SFKs. However, OXSI-2, a Syk inhibitor, significantly reduced c-Cbl phosphorylation at residues Y774 and Y700, without affecting Y731 phosphorylation. Interestingly, PP2 inhibited both platelet spreading on fibrinogen as well as clot retraction, whereas OXSI-2 blocked only platelet spreading, suggesting a differential role of these tyrosine residues. The physiological role of c-Cbl and Y731 was studied using platelets from c-Cbl KO and c-Cbl YF/YF knock-in mice. c-Cbl KO and c-Cbl YF/YF platelets had a significantly reduced spreading over immobilized fibrinogen. Furthermore, clot retraction with c-Cbl KO and c-Cbl YF/YF platelets was drastically delayed.
Introduction
Platelet outside-in signaling is an important process in hemostasis and refers to the process of fibrinogen binding to Fyn associates with the IHDRK sequence on the β3 tail, has a sustained interaction with the integrin through out the platelet activation process, and is postulated as an alternative pathway to support platelet spreading 4 . Syk, on the other hand, is tyrosine phosphorylated in a SFK-dependent manner 5, 6 . The activation of Src kinase and Syk by . Another important function of Cbl proteins is to act as adaptor molecules; they bear a proline-rich region which mediates binding to SH3 domain-containing proteins and on the C-terminal region, Cbl proteins contain several tyrosine phosphorylation sites that regulate their interaction with SH2 domains 11, 12 . Among these phosphorylation sites, tyrosine residue 700 (Y700) in c-Cbl has been described as docking site for Vav 13 while tyrosine residue 774 (Y774) is responsible for Crk/CrkL binding 14, 15 .
Importantly, tyrosine 731 (Y731 in humans; Y737 in mouse) which is unique to cCbl, has been shown to bind to the SH2 domain of the p85 subunit of PI3K
promoting the assembly of a protein complex that regulates PI3K function 16, 17 .
Tyrosine phosphorylation of c-Cbl has been implicated in many signaling pathways. Receptors that lead to c-Cbl phosphorylation includes various Fcγ (e.g. T-cell receptor/CD3, platelet collagen receptor GPVI), growth factor (e.g.
epidermal growth factor receptor), hormones (e.g. prolactin receptor) and
For personal use only. on August 31, 2017. by guest www.bloodjournal.org Given the importance of c-Cbl regulation in integrin signaling in other hematopoietic cell types 6, 18, 20, 26 , we have investigated the mechanism of c-Cbl tyrosine phosphorylation in human platelets and its role in platelet outside-in signaling using platelets from c-Cbl KO mice and c-Cbl YF/YF knock-in mice, in which the tyrosine residue 737 (murine equivalent of human Y731) was mutated to phenylalanine 27, 28 . Here we report that platelet outside-in signaling causes cCbl phosphorylation on Y700, Y731 and Y774. Phosphorylation on residue Y731
is differentially regulated by SFK, whereas Y700 and Y774 are mostly phosphorylated in a Syk-dependent manner. had a reduced spreading and clot retraction was significantly delayed. Our results describe a novel role for c-Cbl in platelet outside-in signaling.
Materials and Methods

Materials
All reagents were obtained from Sigma (St. Louis, MO, USA) unless stated otherwise. Anti-phospho-c-Cbl Y731, Y774, and SFK-phospho Y416 were purchased from Cell Signaling Technology (Denver, MA, USA). Anti-phospho-cCbl Y700, anti-c-Cbl, CD41-PE, JON/A-PE and P-selectin-FITC antibodies were purchased from BD Bioscience (San Jose, CA, USA). Anti-phosphotyrosine antibody 4G10 antibody was from Millipore (Billerica, MA, USA). PP2 and PP3
were from Enzo Life Sciences (Plymouth Meeting, PA, USA). AYPGKF was custom synthesized at Invitrogen (Carlsbad, CA, USA). Spleen Tyrosine Kinase Inhibitor, 3-(1-Methyl-1H-indol-3-yl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide (OXSI-2) was obtained from Calbiochem (San Diego, CA, USA).
Human fibrinogen (plasminogen, vWF and Fibronectin depleted) was from Enzyme Research Laboratories (South Bend, IN, USA). All reagents were analytical grade.
Mice
The generation of c-Cbl KO and c-Cbl YF/YF has been previously described 27, 28 .
Mice were maintained on a mixed C57BL/6JX129SvJ background and 
Studies with Human Platelets
Platelets were isolated from freshly drawn venous blood, collected from healthy volunteers with informed consent and aggregation studies were performed as previously described 29 . The donors claimed not to have taken any medication during two weeks prior to blood collection. Platelet count was adjusted to of 3 x 10 8 platelets/ml for spreading experiments and 2 x 10 8 platelets/ml for aggregation studies.
Studies with Mouse Platelets
Blood was collected from the vena cava of anesthetized mice as previously described
29
. The platelet pellet was resuspended in Tyrode's buffer (pH 7.4) containing 0.2 unit/ml apyrase and 10 μ M indomethacin. Platelet counts were determined using a Hemavet 950FS blood cell counter (Drew Scientific Inc., Dallas, TX, USA). For aggregation studies a density of 2 x 10 8 platelets/ml was used. Flow cytometry was performed as previously described
30
. 
Protein Tyrosine Phosphorylation
Microscopy
Washed human or murine platelets (1 x 10 6 platelets/ml) were plated on fibrinogen-coated cover slips for the indicated time point at 37°C in a CO 2 incubator. When indicated, platelets were treated with PP2 (10
or OXSI-2 (2 μ M) as described above. Adherent cells were fixed with 3.7% paraformaldehyde for 20 min. For confocal microscopy platelets were permeabilized with 0.1% Triton X-100. Rhodamine-phalloidin (Invitrogen, Carlsbad, CA, USA) was used to stain F-actin. Platelets were examined with a confocal system (LEICA TCS FP5 X, Wetzlar, Germany). Images were processed in Adobe Photoshop. Surface areas of at least 20 platelets per experiment were measured using Image-J Software. In other set of experiments human or murine platelets were analyzed by differential interference contrast (DIC) using a Nikon Eclipse TE300 with a digital camera DXM1200 (Nikon Instruments Inc, Melville, NY, USA).
Clot Retraction
Human or murine platelets were isolated as previously described. A suspension of 500 μ l for human platelets and 100 μ l of murine platelets at a concentration of 3 x10 8 platelets/ml was added to a glass cuvette, mixed with 1mM CaCl 2 and 0.2-0.4 units/ml of thrombin. In some experiments, exogenous fibrinogen was added to a final concentration of 0.1 mg/ml. Platelets were allowed to retract and photographed at the indicated time points.
Statistical Analysis
Each experiment was repeated at least 3 times. Results are expressed as means ± S.E.M. with number of observations n. Data was analyzed using GraphPad Prism 5® software. Significant differences were determined using Student´s ttest. Differences were considered significant at p≤ 0.05. IIbβ3 is still poorly understood. To identify the specific tyrosine residues on c-Cbl that are phosphorylated during integrin mediated signaling, we allowed human platelets to spread over a fibrinogen-coated surface. Western blot analysis was performed using phospho-specific antibodies that detect tyrosine phosphorylation sites Y700, Y731 and Y774
12
.
As a robust c-Cbl tyrosine phosphorylation downstream of GPVI has been previously described 23, 24 we used convulxin (Cvx) treated platelets as a positive control. c-Cbl tyrosine phosphorylation occurred by 20 minutes and it was sustained until 45 minutes (Figure 1 ). This result indicates that c-Cbl is phosphorylated on all three tyrosine residues during platelet outside-in signaling.
Regulation of c-Cbl phosphorylation by tyrosine kinases
To elucidate how c-Cbl tyrosine phosphorylation is regulated downstream of integrin signaling in platelets, inhibitor studies were performed. Treatment of platelets with the SFK inhibitor PP2, abolished tyrosine phosphorylation of the residues Y700, Y731, and Y774 on c-Cbl (Figure 2A ), while PP3 (negative control) had no effect. Densitometry analysis showed that PP2 inhibition is Figure 4A , SFK or Syk inhibition results in decreased platelet spreading, suggesting that among other events, c-Cbl phosphorylation on residues Y700, Y731 and Y774 may be important for platelet spreading. In contrast to the spreading experiments, clot retraction was only affected when platelets were treated with PP2 whereas Syk inhibition had no effect ( Figure 4B 
Discussion
Platelet outside-in signaling is an important event in hemostasis and thrombosis as it mediates intracellular responses that regulate thrombus growth and stability.
However, many of the signaling mechanisms downstream of integrin activation are poorly understood. c-Cbl has been identified as a protein activated by integrins 8, 19, 20, 25, 26 and through its phosphorylated tyrosine residues, it mediates signaling cascades by recruiting Vav, PI3K and Crk/CrkL 11, 16, 17 . Nonetheless, the physiological role of c-Cbl integrin-mediated signaling and the mechanism of phosphorylation of the tyrosine residues in platelets are not determined. We report that, upon activation, c-Cbl undergoes tyrosine phosphorylation on its three major phosphorylation sites Y700, Y731 and Y774 and it plays a pivotal role in platelet αIIbβ3-mediated functional responses.
Using pharmacological inhibitors we have identified that c-Cbl tyrosine residues are differentially phosphorylated in a SFK and Syk-dependent mechanism (outlined in Figure 7C ). The role of SFKs in outside-in signaling has been established and is known to be proximal to the integrin 2, 34 . Of the several SFKs rather than the phosphorylation of Y700 and Y774, which is dependent on Syk activity ( Figure 3A ). Because Syk catalytic activity requires SFK activation we would anticipate that phosphorylation of these tyrosine residues is temporally regulated. ; the subsequent phosphorylation events and the preference of SFK for Y731 over Y700 and Y774 might relate to its recognition motif. Although the three tyrosines are surrounded by motifs recognized by Src, Y731 lies in a consensus sequence (Y731EAM) that contains elements considered highly specific for Src recognition 39, 40 .
In order to understand the functional outcome of c-Cbl differential tyrosine phosphorylation we also examined the effect of inhibiting the kinases responsible for c-Cbl phosphorylation and correlated these results with two major outside-in signaling outcomes: platelet spreading and clot retraction. We found excellent correlation between SFK inhibition (and hence inhibition of phosphorylation of all three tyrosines) and both spreading and clot retraction. However, Syk inhibition correlated with platelet spreading but not with clot retraction. As Y731 phosphorylation was unaffected by Syk inhibition, we postulated that this phosphorylation plays an important role in platelet spreading and clot retraction (outlined in Figure 7C ). On the other hand phosphorylation of Y700 and Y774 might only play a role in spreading by the possible recruitment of Vav and Crk/CrKL. This is consistent with the decreased spreading phenotype observed in Vav1/3 -/-platelets 1 9
To further evaluate the role of Y731 phosphorylation, we investigated platelet outside-in signaling in c-Cbl KO and in c-Cbl YF/YF . We chose to target Y731, in preference to Y700 or Y774, because this site is unique to c-Cbl, i.e. it is not present in Cbl-b, and because several studies have showed that pY731 recruits p85 promoting the activation of PI3K 11, 16, 17 . Therefore targeting this site in mouse would determine the in vivo significance of a c-Cbl-specific function that . Furthermore, we found that Syk is equally activated in c-Cbl YF/YF and WT platelets allowed to spread on fibrinogen Figure 3C ). These findings indicate that phosphorylation of c-Cbl Y731 is not involved in Syk activation per se. An alternative possibility is that phosphorylation of Y731 induces a conformational changes in c-Cbl that makes additional tyrosine residues more accessible to the kinase domain of Syk.
Further studies are needed to determine the precise mechanism by which phosphorylation of c-Cbl on Y731 supports Syk-dependent phosphorylation of Y700 and Y774.
Considering that PI3K is by far the best known partner of Y731 and that PI3K function is of great importance in platelet outside-in signaling 46,47 , phosphorylation of Y731 is an event that might be critical for proper localization and function of PI3K. Thus, we speculate that Y731 phosphorylation is rapidly needed after integrin engagement; being regulated by SFKs, whose activation occurs rapidly after fibrinogen binding, will promptly create a docking site for PI3K. Nonetheless, we cannot rule out the possibility that the defects seen in the c-Cbl YF/YF are due to some other unidentified Y731 partners. Consistent with our speculation, we have recently shown that PI3K activity is upregulated in cCbl YF/YF osteoclasts, indicating that c-Cbl-PI3K interaction provides a regulatory effect in various signaling pathways 42 . Whether this is the case in platelets remains to be investigated, but the similarities between integrin signaling in different cell types may indicate that the mechanism delineated here of α IIbβ3 signaling may be relevant to integrins in a variety of biological contexts.
In conclusion, we propose a platelet outside-in signaling mechanism in which c- Cbl adapter function is necessary for the formation of signaling complexes in the appropriate location and time. As per our model ( Figure 7C ) interactions among c-Cbl, Src and Syk result in actin cytoskeleton rearrangement, filopodia and lamellipodia formation, spreading and clot retraction.
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